Jefferies Initiates Coverage On Pfizer with Hold Rating, Announces Price Target of $43
Jefferies analyst Akash Tewari initiates coverage on Pfizer (NYSE:PFE) with a Hold rating and announces Price Target of $43.
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable…
Top 15 Trending Stocks On WallStreetBets As Of Thursday, Mar. 2, 2023 (Via Swaggy Stocks)
Data from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
Tesla (TSLA)
Nvidia (NVDA)
Salesforce (CRM)
C3.ai (AI)
Snowflake (SNOW)
Amazon (AMZN)
Apple (AAPL)
Invesco QQQ Trust
Cue Health Collaborates With Pfizer To Provide People Who Test Positive For COVID-19 With Actionable Health Information To Better Inform their Treatment Journey
New educational resources will make it easier for people at high risk of progression to severe COVID-19 to protect their health through accessible and timely health information
Cue Health ("Cue")
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK’s Candidate Soon After Pfizer’s
The FDA’s Vaccines and Related Biological Products Advisory Committee voted that GSK plc’s (NYSE:GSK) available data support the safety and effectiveness of…
Jim Cramer Says He’s Known Novavax Is ‘Worthless’ For ‘Very Long Time,’ Trashes Company For Being Too ‘Promotional’
Novavax Inc (NASDAQ: NVAX) shares are crashing Wednesday after the company warned that substantial doubt exists regarding its ability to continue.
Jim Cramer isn't surprised.
FDA AdComm Gives Thumbs Up To Pfizer’s RSV Vaccine Candidate For Elderly People
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted in favor of Pfizer Inc’s (NYSE:PFE) available data is adequate to…
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…
Pfizer Unusual Options Activity For February 28
Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test.